文献速递前列腺癌前列腺增生与排尿功能障碍

健康效用测量前列腺癌幸存者常见病症的影响

Measuring the Impact of Common Prostate Cancer Survivorship Conditions With Health Utilities.
PubMed 文献 · Urology · 2026-01-29

本研究通过标准化临床情景和四种健康状态效用工具,比较疾病暴露组与疾病初治组对前列腺癌幸存者常见病症(压力性尿失禁和勃起功能障碍)及其手术治疗影响的感知。结果显示疾病暴露组对健康影响评分显著更低,压力性尿失禁影响大于勃起功能障碍,人工尿道括约肌改善效用,而阴茎假体无显著影响。

要点

  • 疾病暴露组对ED和SUI的健康影响感知显著低于疾病初治组。
  • 两组均认为SUI对健康的影响大于ED(P<.001)。
  • AUS治疗改善QALY,IPP无统计学显著影响,但存在组内异质性。

核心结论

  • 健康状态效用可客观比较不同队列和病症的疾病影响,并评估手术干预的感知影响。
  • 疾病暴露组表现出疾病适应现象,手术干预的感知影响存在异质性。

研究设计与样本

  • 两组队列:疾病暴露组(DE)为接受前列腺癌治疗的患者(n=42),疾病初治组(DN)从Qualtrics招募(n=196)。
  • 使用标准化临床情景评估压力性尿失禁(SUI)和勃起功能障碍(ED),采用四种健康状态效用(HSU)工具取平均值,以质量调整生命年(QALY)表示(范围0.0死亡至1.0完美健康)。
  • 评估阴茎假体(IPP)和人工尿道括约肌(AUS)对健康的影响,比较不同病症和队列的QALY。

主要发现

  • DE队列对所有病症的健康影响评分显著低于DN队列(ED +0.14 QALY,SUI +0.11 QALY)。
  • 两组均认为SUI(QALY 0.60, 0.71)对健康的影响大于ED(QALY 0.65, 0.79;P<.001)。
  • IPP治疗未显著影响总体平均QALY(+0.02, +0.02;P=.38)。
  • AUS治疗改善QALY(+0.04, +0.07;P<.001)。
  • 亚组分析显示IPP和AUS影响的组内异质性显著,20%-25%的队列报告QALY改善>17%(临床显著)。

临床怎么用

  • 临床决策中可参考健康效用值评估不同病症对患者健康的影响权重。
  • 需注意患者对疾病影响的感知因暴露史而异,疾病适应可能降低感知影响。
  • 手术干预的效用改善存在个体差异,应个体化评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the effect of disease exposure on the perceived impact of common prostate cancer (CaP) survivorship conditions and their surgical treatments. MATERIALS AND METHODS: Two cohorts-disease-exposed (DE) patients treated for CaP and disease naïve (DN) recruited from Qualtrics-were given standardized clinical scenarios on stress urinary incontinence (SUI) and erectile dysfunction (ED) and asked to assess disease impact using four health state utility (HSU) instruments which were averaged and reported in Quality-Adjusted-Life-Years (QALY; range 0.0 [death] to 1.0 [perfect health]). We then assessed the impact that inflatable penile prosthesis (IPP) and artificial urinary sphincter (AUS) had on health. QALYs were compared by condition and cohort. RESULTS: Cohorts included 196 DN and 42 DE participants. The DE cohort rated all conditions to have significantly less impact on health than the DN cohort (+0.14 QALY for ED and +0.11 QALY for SUI). Both cohorts rated SUI (QALY 0.60, 0.71) to have more impact than ED (QALY 0.65, 0.79; P<.001). ED treatment with IPP did not statistically impact the overall mean QALY in either group (+0.02, +0.02; P = .38). SUI treatment with AUS improved QALY in both (+0.04, +0.07; P<.001). Subanalysis revealed significant group heterogeneity in the impact of IPP and AUS, with 20%-25% of the cohorts reporting a QALY improvement of >17% (clinically significant). CONCLUSION: We demonstrate how HSUs can provide a measure of disease impact in both DN and DE cohorts, allowing for an objective, standard comparison between cohorts and between conditions, including the ability to assess the perceived impact of surgical interventions. Evidence for disease adaptation in the DE cohort and heterogeneity of perceived impact of surgical interventions was demonstrated.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Hansen SC, Schlaepfer CH, Shane DM, et al. Measuring the Impact of Common Prostate Cancer Survivorship Conditions With Health Utilities. Urology. 2026. PMID: 41620133. doi:10.1016/j.urology.2026.01.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。